Detaillierte Beitrags-Information

Zurück zur Liste

Beitragstitel Percutaneous image-guided cryoablation of sacral chordoma
Beitragscode P091
Autoren
  1. Aurélien Traverso CHUV Vortragender
  2. Alexander A. Bazan
  3. Nicolas Gallusser CHUV, Centre Hospitalier Universitaire Vaudois
  4. Sami Abou-Khalil
  5. Patrick Goetti CHUV & University of Lausanne
  6. Laurent Mustaki eHnv Hôpital Yverdon Les Bains
  7. Frédéric Vauclair Bone and Motion Center, Hirslanden Lausanne
  8. Igor Letovanec Centre hospitalier universitaire de Lausanne
  9. Georgia Tsoumikadou
  10. Michael Montemurro Lausanne University Hospital (CHUV)
  11. Stéphane Cherix CHUV - Centre hospitalier universitaire vaudois
Präsentationsform Poster
Themengebiete
  • A07 - Spezialgebiet 3 | Tumore
Abstract Introduction
Chordoma is an uncommon primary malignant bone tumour of the spine. The most common location is the sacrococcygeal area (40-50%) followed by the base of the skull (35-40%) and finally from the vertebral bodies (15-20%).
Sacral chordoma is difficult to manage,even with the advance in the surgical techniques, chemotherapy or radiotherapy. The optimal treatment remains unclear.
Percutaneous imaging-guided cryoablation (PCA) is a relatively recent technique where it is applied, by means of cryoprobe, an extreme cold that allows to destroy tumors under Imaging control.
According to our knowledge, percutaneous image-guided cryoablation as primary or recurrent treatment of chordomas has not been described in the English literature.
The purpose of our retrospective study is to analyze the results of selected patients, treated by percutaneous image-guided cryoablation in sacral chordoma, when surgical treatment was overtaken.
Materials and methods
We retrospectively reviewd our database and identified four patients with sacral chordoma treated with percutaneous image-guided cryoablation. We analyzed feasibility, time to local progression, pain release and finally survival.The mean follow-up was a 42 months (Range 15-65).
Results
All four patients had acceptable pain release. Local recurrence occurred in all four. Time to progression was 14 months (range 5-18). At last follow-up visit, all patients were alive with the disease.
Conclution
Percutaneous imaging-guided cryoablation is a viable mini invasive method to treat recurrent chordomas, when standard treatment alternatives are not available anymore. More patients are needed to confirm this favorable preliminary evaluation.